Proposals related to affordability and pricing of pharmaceuticals including issues related to H. R. 2212 and S. 974, CREATES Act of 2017; H. R. 2051 - FAST Generics Act.
Proposals related to affordability and pricing of pharmaceuticals including H. R. 2212 and S.974 Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; H. R. 2051 - FAST Generics Act.
Provisions affecting the Medicaid rebate program included in the Bipartisan Budget Act of 2015.
Duration: February 1, 2017
to
January 31, 2018
General Issues: Health Issues , Pharmacy , Medicare/Medicaid , Taxation/Internal Revenue Code , Government Issues
Spending: about $240,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2017: U.S. Senate, House of Representatives
Related Foreign Entities:
OrvetUK (Morely Leeds, GBR); contribution to lobbying: $0; ownership 100%; Teva Pharmaceuticals EuropeBV (Mijdrecht, NED); contribution to lobbying: $0; ownership 100%; Teva Pharmaceutical Industries, Ltd. (Petach Tikva, ISR); contribution to lobbying: $0; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Lisa Kountoupes Deputy Asst.to the President&House Liaison, Special Assistant to the President for Legislative Affairs, Asst. Director for Legislative Affairs at OMB, Special Asst. to Undersecretary, Dept.of Energy,Policy Advisor to Chairman of Energy&Commerce Comm.
Lori Denham Chief of Staff, Legislative Director, Legislative Assistant, Senior Policy Advisor, Communications Director, Staff Assistant - Rep. Cal Dooley, D-CA; Legislative Director - Rep. Darlene Hooley, D-OR
Julie Hershey Carr Senior Policy Advisor, Legislative Director, Legislative Assistant - Rep. Joe Pitts, R-PA
Randi Reid Legislative Director, Legislative Assistant and Projects Director, Legislative Assistant - Senator Michael Enzi, R-WY; Legislative Director - Rep. Michael Burgess, R-TX
Rose Sullivan Chief of Staff, Legislative Director, Legislative Assistant, Outreach Director, Constituent Services Advocate - Senator Amy Klobuchar, D-MN
David Peluso Chief of Staff - Representative Cathy McMorris Rodgers, R-WA; Chief of Staff, Communications Director, Legislative Assistant, Deputy Press Secretary and Executive Assistant - Representative Gus Bilirakis, R-FL
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2018
In Q1, Kountoupes Denham Carr & Reid, LLC lobbied for TEVA Pharmaceuticals USA, Inc. , earning $20,000. The report was filed on April 20, 2018.
Original Filing: 300953372.xml
Lobbying Issues
Proposals related to affordability and pricing of pharmaceuticals including issues related to H. R. 2212 and S. 974, CREATES Act of 2017; H. R. 2051 - FAST Generics Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Proposals related to affordability and pricing of pharmaceuticals including H. R. 2212 and S.974 Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; H. R. 2051 - FAST Generics Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions affecting the Medicaid rebate program included in the Bipartisan Budget Act of 2015.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
Kountoupes Denham Carr & Reid, LLC terminated an engagement in which they represented TEVA Pharmaceuticals USA, Inc. on April 20, 2018.
Original Filing: 300953403.xml
Lobbying Issues
Proposals related to affordability and pricing of pharmaceuticals including issues related to H. R. 2212 and S. 974, CREATES Act of 2017; H. R. 2051 - FAST Generics Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Proposals related to affordability and pricing of pharmaceuticals including H. R. 2212 and S.974 Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; H. R. 2051 - FAST Generics Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions affecting the Medicaid rebate program included in the Bipartisan Budget Act of 2015.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Kountoupes Denham Carr & Reid, LLC lobbied for TEVA Pharmaceuticals USA, Inc. , earning $60,000. The report was filed on Jan. 18, 2018.
Original Filing: 300927329.xml
Lobbying Issues
Proposals related to affordability and pricing of pharmaceuticals including issues related to H. R. 2212 and S. 974, CREATES Act of 2017; H. R. 2051 - FAST Generics Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the proposed border adjustment tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Proposals related to affordability and pricing of pharmaceuticals including H. R. 2212 and S.974 Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; H. R. 2051 - FAST Generics Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions affecting the Medicaid rebate program included in the Bipartisan Budget Act of 2015.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, Kountoupes Denham Carr & Reid, LLC (formerly reporting as Kountoupes Denham LLC) lobbied for TEVA Pharmaceuticals USA, Inc. , earning $60,000. The report was filed on Oct. 19, 2017.
Original Filing: 300909668.xml
Lobbying Issues
House and Senate efforts to repeal and replace the Affordable Care Act including amendments to the H. R. 1628, the Affordable Health Care Ace of 2017, including versions of the Better Care Reconciliation Act as well as the Graham-Cassidy proposal. Proposals related to affordability and pricing of pharmaceuticals including draft Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; H. R. 2051 - FAST Generics Act; S.771- Improving Access to Affordable Drugs Act; S.469-Affordable and Safe Prescription Drug Importation Act: and H. R. 749-Lower Drugs Through Competition Act. Issues related to industry user fee agreements, including the Prescription Drug User Fee Agreement and the Generic Drug User Fee Agreement and H.R. 2430, the FDA Reauthorization Act of 2017, and S.934, the FDA Reauthorization Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to comprehensive tax reform and the proposed border adjustment tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Proposals related to affordability and pricing of pharmaceuticals including H. R. 2212 and S.974 Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; H. R. 2051 - FAST Generics Act; Issues related to industry user fee agreements, including the Prescription Drug User Fee Agreement and the Generic Drug User Fee Agreement and H.R. 2430, the FDA Reauthorization Act of 2017, and S.934, the FDA Reauthorization Act of 2017. Issues related to opioid abuse.
Agencies Lobbied
U.S. Senate
Lobbying Issues
House and Senate efforts to repeal and replace the Affordable Care Act including amendments to the H. R. 1628, including the Affordable Health Care Act of 2017, and versions of the Better Care Reconciliation Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Kountoupes Denham LLC lobbied for TEVA Pharmaceuticals USA, Inc. , earning $60,000. The report was filed on July 20, 2017.
Original Filing: 300896640.xml
Lobbying Issues
H. R. 1628-American Health Care Act: Medicaid Rebate provision of the Bipartisan Budget Act of 2015; Proposals related to affordability and pricing of pharmaceuticals including draft Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; H. R. 2051 - FAST Generics Act; S.771- Improving Access to Affordable Drugs Act; S.469-Affordable and Safe Prescription Drug Importation Act: and H. R. 749-Lower Drugs Through Competition Act. Issues related to industry user fee agreements, including the Prescription Drug User Fee Agreement and the Generic Drug User Fee Agreement and H.R. 2430, the FDA Reauthorization Act of 2017, and S.934, the FDA Reauthorization Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to comprehensive tax reform and the proposed border adjustment tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Proposals related to affordability and pricing of pharmaceuticals including S.974 Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; H. R. 2051 - FAST Generics Act; Issues related to industry user fee agreements, including the Prescription Drug User Fee Agreement and the Generic Drug User Fee Agreement and H.R. 2430, the FDA Reauthorization Act of 2017, and S.934, the FDA Reauthorization Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the confirmation of FDA Commissioner.
Lobbying Issues
H. R. 1628-American Health Care Act and the Senate version, the Better Care Reconciliation Act: Medicaid Rebate provision of the Bipartisan Budget Act of 2015. H. R. 2430, the FDA Reauthorization Act of 2017, and S.934, The FDA Reauthorization Act of 2017.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Kountoupes Denham LLC lobbied for TEVA Pharmaceuticals USA, Inc. , earning $40,000. The report was filed on April 20, 2017.
Original Filing: 300876349.xml
Lobbying Issues
Issues related to affordability and pricing of pharmaceuticals. Issues related to industry user fee agreements, including the Prescription Drug User Fee Agreement and the Generic Drug User Fee Agreement. Issues related to H.R. 1628, the American Health Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about the pharmaceutical industry. Issues related to affordability and pricing of pharmaceuticals including S.771 Improving Access to Affordable Prescription Drugs Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to comprehensive tax reform and the proposed border adjustment tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2017
Kountoupes Denham LLC amended a lobbying report for representation of TEVA Pharmaceuticals USA, Inc. in Q12017 on April 20, 2017.
Original Filing: 300876989.xml
Lobbying Issues
H. R. 1628-American Health Care Act: Medicaid Rebate provision of the Bipartisan Budget Act of 2015; Proposals related to affordability and pricing of pharmaceuticals including draft Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; H. R. 2051 - FAST Generics Act; S.771- Improving Access to Affordable Drugs Act; S.469-Affordable and Safe Prescription Drug Importation Act: and H. R. 749-Lower Drugs Through Competition Act. Issues related to industry user fee agreements, including the Prescription Drug User Fee Agreement and the Generic Drug User Fee Agreement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to comprehensive tax reform and the proposed border adjustment tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...